Immunai has signed an up-to-$85M deal with AstraZeneca to develop a new therapeutic target for inflammatory bowel disease (IBD). The target was discovered using Immunai’s Immunodynamics Engine (IDE), which applies machine learning to single-cell multi-omics data from its immune cell atlas, AMICA.
This marks a shift from their oncology-focused work launched in 2022, expanding AstraZeneca’s stake in AI-powered immune mapping. With IDE now integrating 300,000+ patient samples, the partnership could redefine immune-driven drug discovery—potentially accelerating therapies for IBD and beyond.